$ESPR What has started in the EU will show up in the USA markets in 2026. First comes prescription increases. Then comes sales. The stock price will adjust accordingly.

Snoozer on $OMER HCW reits. 20 PT YARTEMLEA (Narsoplimab) Approval Is a Significant Validation of OMER Value "Going into 2026, we believe OMER has the potential to continue to reward investors. We highlighted OMER as one of our best ideas for 2025, and we think there remains

Ted Karidis $MREO is rare disease: every one underestimated the true potential of Setru. If approved and shown superior then Bisphosphonates the demand will skyrocket off label breast, colorectal, endometrial, prostate, myeloma cancer

Appears the 14-15 dollar level on $OMER is seeing sustained buying. Interesting development, Biotech not my strong suit, but appears to be strong catalyst with sustained price action.

I've heard that $PLTR looks terrible here at each of these arrow spots.

$INTC UPGRADED AS A BUY BY MELIUS RESEARCH - PRICE TARGET: $50

$INTC is one of the most undervalued stocks in the market right now. Real innovation clear focus and tangible results are finally showing up. This is strong confirmation that 18a is not only ready but genuinely disruptive. 14a looks even more compelling. Together they outline a

Bruce Booth $OMER is another reminder that entry point > story. Being early or late on catalysts often matters more than conviction alone. After 3yrs of FDA issues it was priced for failure($150M cap) Then things changed: – FDA approval (Yartemlea, TA-TMA) – $240M upfront cash from $NVO

$MP MP Materials Double bottom and now trading back into a massive supply Break and hold above supply at $65 and can target would be $82 then $100 Or another scenario would be a fail of supply and come back to $50 demand level

I am officially calling it… $BABA is about to see another euphoric upside squeeze in the coming weeks. The last time I called for a similar run $BABA had rallied from $80 to over $190+ This time around I’m projecting $220-$240+ to hit. Save this post to look back on later…

Hilariously, $SMMT admits that it actually submitted the filing in Q4. So it appears to have been sitting on this, hoping FDA acceptance would come in time for a #JPM26 splash. That's not happened.

Citi upgraded Palantir $PLTR to Buy and raised its price target to $235 from $210. Analyst Tyler Radke says 2026 consensus estimates look set to move “significantly higher” as enterprise use cases accelerate, based on Citi’s CIO survey and industry conversations. Citi also

$META has been down quite a lot over the past few months mainly because of higher-than-expected AI CAPEX outlook, which will impact its margins and FCF in the coming quarters. In my view, this is a temporary headwind. Meta’s core social media and advertising business fundamentals

I'm not sure how much further Fiverr $FVRR can fall, but it's starting to look ludicrously undervalued now. Just like $ADBE and $DUOL, this is another stock that seems to be getting wrecked on fears that AI will destroy their business, in this case because AI can do many of the

$INTC I know, I know not another one of these memes!!! But just one last time for good measure. Promise.

David Zinsner’s insider trade represents approximately 30.9% of his base salary of $808,300. To anyone who is claiming this is not enough… let’s see you put in 30.9% of your annual salary anywhere without actual conviction. $INTC

$INTC Intel CFO, David Zinsner, purchases $250k worth of shares at $42.50 / share.

Palantir can't stop and won't stop $PLTR